Table 3.
Major clinical evidence for dynamic first-pass CE-perfusion ADCT.
| Authors | Method | Target | Parameters | Cutoff Values (HU) | SE (%) | SP (%) | AC (%) |
|---|---|---|---|---|---|---|---|
| Ohno Y, et al. [5] | 320-detector row CT | Pulmonary nodules | Perfusion (mL/100 mL/min) calculated with single-input maximum slope method | 40.0 | 98 (42/43) | 79 (26/33) | 90 (68/76) |
| Extraction fraction (mL/100 mL/min) | 2.0 | 88 (38/43) | 82 (27/33) | 86 (65/76) | |||
| Blood volume (mL/100 mL) | 2.0 | 86 (37/43) | 54 (18/33) | 72 (55/76) | |||
| FDG-PET/CT | SUVmax | 2.0 | 91 (39/43) | 52 (17/33) | 74 (56/76) | ||
| Ohno Y, et al. [12] | 320-detector row CT | Pulmonary nodules | Total perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 40 | 86.0 (49/57) | 79.5 (31/39) | 83.3 (80/96) |
| Perfusion (mL/100 mL/min) calculated with single-input maximum slope method | 20 | 64.9 (37/57) | 69.2 (27/39) | 66.7 (64/96) | |||
| FDG-PET/CT | SUVmax | 2.5 | 63.2 (36/57) | 56.4 (22/39) | 60.4 (58/96) | ||
| Ohno Y, et al. [15] | 320-detector row CT | Pulmonary nodules | Total perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 29 | 92 (123/133) | 71 (60/85) | 84 (183/218) |
| Nodule perfusion (mL/100 mL/min) calculated with single-input maximum slope method | 10 | 91 (121/133) | 28 (24/85) | 67 (145/218) | |||
| Dynamic first-pass CE-perfusion MRI for 1.5T system | Maximum relative enhancement | 0.13 | 92 (123/133) | 49 (42/85) | 76 (165/218) | ||
| Slope of enhancement | 0.016 | 93 (124/133) | 49 (42/85) | 76 (166/218) | |||
| FDG-PET/CT | SUVmax | 2 | 89 (119/133) | 31 (26/85) | 67 (145/218) | ||
| Ohno Y, et al. [20] | 320-detector row CT | Lymph node metastasis in NSCLC analyzed per node | Total perfusion (mL/100 mL/min) calculated with slope of enhancement dual-input maximum slope method | 58 | 54.2 (32/59) | 89.8 (53/59) | 72.0 (85/118) |
| Systemic arterial perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 4.1 | 98.3 (58/59) | 56.4 (51/59) | 92.4 (109/118) | |||
| Permeability surface (mL/100 mL/min) assessed with Patlak plot method | 8.7 | 50.8 (30/59) | 94.9 (56/59) | 72.9 (86/118) | |||
| Distribution volume (mL/100 mL) assessed with Patlak plot method | 0.37 | 84.7 (50/59) | 44.1 (26/59) | 64.34 (76/118) | |||
| FDG-PET/CT | SUVmax | 2.9 | 74.6 (44/59) | 91.5 (54/559) | 83.1 (98/118) | ||
| Seki S, et al. [22] | 320-detector row CT | Therapeutic outcome prediction for NSCLC | Total perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 29.2 | 78.3 (18/23) | 85 (17/20) | 81.4 (35/43) |
| Pulmonary arterial perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 15.5 | 65.2 (15/23) | 80 (16/20) | 72.1 (31/43) | |||
| Systemic arterial perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 11 | 82.6 (19/23) | 80 (16/20) | 81.4 (35/43) | |||
| Dynamic first-pass CE-perfusion MRI at 3T system | Total perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 37.5 | 69.6 (16/23) | 95 (19/20) | 81.4 (35/43) | ||
| Pulmonary arterial perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 16.3 | 65.2 (15/23) | 80 (16/20) | 72.1 (35/43) | |||
| Systemic arterial perfusion (mL/100 mL/min) calculated with dual-input maximum slope method | 16.5 | 82.6 (19/23) | 80 (16/20) | 81.4 (35/43) | |||
| FDG-PET/CT | SUVmax | 5.7 | 87.0 (20/23) | 76.9 (14/20) | 79.1(34/43) |
SE: sensitivity, SP: specificity, AC: accuracy, NSCLC: non-small-cell lung cancer; number following author’s name corresponds to number in References.